Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cancer and immunologic therapeutics developer Seattle Genetics has been issued two key US patents relating to the company's SGN-40 anticancer program, which is currently being evaluated in multiple myeloma and lymphoma.
Subscribe to our email newsletter
Seattle Genetics is currently conducting phase I clinical trials of SGN-40, an anti-CD40 antibody, in multiple myeloma and non-Hodgkin’s lymphoma. The company plans to initiate an additional phase I study in chronic lymphocytic leukemia during the first half of 2005.
“We believe SGN-40 has significant therapeutic potential in multiple types of cancer and immunologic diseases, and our expanding intellectual property portfolio further strengthens this program,” stated Eric Dobmeier, vice president of corporate affairs and general counsel of Seattle Genetics.
SGN-40 is a humanized monoclonal antibody that targets the CD40 antigen, which is expressed on most B-cell lineage hematologic malignancies, including multiple myeloma, non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Seattle Genetics is also considering potential applications of SGN-40 in other indications such as certain solid tumors and immunologic diseases.